mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics.
Pópulo
H
H
Soares
P
P
Faustino
A
A
Rocha
A S
AS
Silva
P
P
Azevedo
F
F
Lopes
J M
JM
D018450:Disease Progression; D006801:Humans; D008545:Melanoma / Q000175:diagnosis* / Q000201:enzymology* / Q000473:pathology; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
D009363:Neoplasm Proteins; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases